Last reviewed · How we verify
NCT06104917
Effect of Maolactin on Gastrointestinal Tract (GIT) Health
Phase 3 trial testing High Dose Maolactin in Gastrointestinal Dysfunction in 91 participants. Completed in 23 July 2025.
23 July 2025
Quick facts
| Lead sponsor | RDC Clinical Pty Ltd |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 91 |
| Start date | 21 February 2024 |
| Primary completion | 23 July 2025 |
| Estimated completion | 23 July 2025 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- High Dose Maolactin — full drug profile →
- Low Dose Maolactin — full drug profile →
- Maltodextrin (MALTODEXTRIN) — full drug profile →
Conditions studied
- Gastrointestinal Dysfunction — all drugs for Gastrointestinal Dysfunction →
Sponsor
RDC Clinical Pty Ltd — full company profile →
Who can join
18 and older, any sex, with Gastrointestinal Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, double-blind, placebo-controlled, 3 arm parallel group study of 12 weeks duration, with a 4-week run-in period as the control phase and an 8-week intervention period, to investigate the effectiveness of the treatment on upper GI disturbance.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06104917
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastrointestinal Dysfunction
Currently open trials in the same condition.
- NCT07252102 — Effect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients · NA · recruiting
- NCT06510348 — Achieving nuTritional Target in criticAlly Ill patieNts With iMpairEd gastroiNtesTinal Dysfunction · NA · recruiting
- NCT06740903 — Evaluating Perioperative Outcomes: Dexmedetomidine vs Lignocaine in Laparoscopic Chlolecystectomy · Phase 2, PHASE3 · recruiting
- NCT06386471 — Personalized GI Motility Responses to Diet · NA · recruiting
- NCT05344417 — Low Pressure Pneumoperitoneum and Postoperative Ileus · NA · recruiting
Other RDC Clinical Pty Ltd trials
Trials by the same sponsor.
- NCT06878001 — CaroRite™ for Skin Health and Signs of Ageing · Phase 4 · completed
- NCT06907680 — M-Gard Particulate EW Efficacy Study on Seasonal Allergic Rhinitis · Phase 2 · completed
- NCT06837961 — LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases · Phase 3 · completed
- NCT06827327 — LC-Plasma for Preventing URTIs and Reducing Symptoms · Phase 3 · completed
- NCT06840080 — OEA and LipiSperse Metabolic Study · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06104917 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RDC Clinical Pty Ltd
- Last refreshed: 26 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06104917.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing